WO2017208136A1 - Pharmaceutical composition of dapagliflozin co-crystal - Google Patents

Pharmaceutical composition of dapagliflozin co-crystal Download PDF

Info

Publication number
WO2017208136A1
WO2017208136A1 PCT/IB2017/053155 IB2017053155W WO2017208136A1 WO 2017208136 A1 WO2017208136 A1 WO 2017208136A1 IB 2017053155 W IB2017053155 W IB 2017053155W WO 2017208136 A1 WO2017208136 A1 WO 2017208136A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
dapagliflozin
oral pharmaceutical
crystal
citric acid
Prior art date
Application number
PCT/IB2017/053155
Other languages
French (fr)
Inventor
Suhani Sinha
Anil MAKWANA
Simrata Bedi
Ravi Kochhar
Ravindra Agarwal
Original Assignee
Sun Pharmaceutical Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Limited filed Critical Sun Pharmaceutical Industries Limited
Priority to KR1020237012428A priority Critical patent/KR20230056789A/en
Priority to KR1020187036843A priority patent/KR20190015329A/en
Publication of WO2017208136A1 publication Critical patent/WO2017208136A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present disclosure relates to oral pharmaceutical compositions comprising dapagliflozin citric acid co-crystal and one or more pharmaceutically acceptable excipients, and processes for their preparation.
  • the disclosure further relates to methods of treating diabetes using said pharmaceutical compositions.
  • Dapagliflozin is a SGLT2 inhibitor, chemically known as (25,3R,4R,55,6R)-2-[4- chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
  • Current commercially available formulations of dapagliflozin contain a propanediol (propylene glycol) monohydrate solvate of dapagliflozin as the active ingredient.
  • the commercially available dapagliflozin is crystalline in nature. In contrast, dapagliflozin base can exist in amorphous form.
  • U.S. Patent No. 6,515,117 reports the compound dapagliflozin.
  • U.S. Patent No. 7,919,598 reports a (S)-propylene glycol solvate of dapagliflozin and processes of preparation thereof.
  • U.S. Patent Nos. 7,851 ,502, 8,221 ,786, and 8,361 ,972 reports pharmaceutical compositions comprising dapagliflozin or dapagliflozin propylene glycol hydrate and specific excipients in given amounts.
  • U.S. Patent No. 8,221 ,786 further reports pharmaceutical compositions in the form of a stock granulation comprising dapagliflozin propylene glycol hydrate and excipients.
  • PCT Publication No. WO 2012/163546 reports pharmaceutical compositions comprising cyclodextrin and dapagliflozin, in some embodiments as an inclusion complex.
  • PCT Publication No. WO 2015/011113 reports pharmaceutical compositions comprising amorphous solid dispersions of dapagliflozin or adsorbates of dapagliflozin with one or more pharmaceutically acceptable excipients.
  • dapagliflozin and a solid dispersion comprising the same.
  • the present disclosure relates to oral pharmaceutical compositions comprising dapagliflozin citric acid co-crystal and one or more pharmaceutically acceptable excipients.
  • the dapagliflozin citric acid co-crystal is present in an amount of from about 0.5% to about 25% in weight of the active moiety, based on the total weight of the composition.
  • the oral pharmaceutical composition of the present invention is prepared by a wet granulation process or by a dry process, such as direct compression and dry granulation.
  • the present disclosure provides oral pharmaceutical formulations comprising dapagliflozin citric acid co-crystal, especially a solid oral dosage form, such that the therapeutic benefits of the dapagliflozin may be delivered to a patient in need thereof.
  • the present invention provides a stable oral pharmaceutical formulation which is easy to manufacture, provides an acceptable dose uniformity, and provides a rapid dissolution profile.
  • the disclosure provides an oral pharmaceutical composition comprising dapagliflozin citric acid co-crystal and one or more pharmaceutically acceptable excipients.
  • the dapagliflozin citric acid co-crystal is from about 0.5% to about 25%, about 1% to about 20%, about 2% to about 15%, about 3% to about 10%, or about 4% to about 8% by weight of the total weight of the composition. According to some embodiments, the dapagliflozin citric acid co-crystal is from about 0.5% to about 25% by weight of the total weight of the composition. In some
  • the dapagliflozin citric acid co-crystal is from about 4% to about 8% by weight of the total weight of the composition.
  • “%” and “percentage” when referring to amounts of active agent or excipients refers to wt%, e.g., the weight of the active agent or excipient relative to the weight of the total composition.
  • the dapagliflozin citric acid co-crystal is present in an amount of from about 1 mg to about 100 mg, about 2 mg to about 75 mg, about 3 mg to about 50 mg, about 4 mg to about 40 mg, about 5 mg to about 25 mg in the
  • the dapagliflozin citric acid co-crystal is present in an amount of about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 12 mg, about 15 mg, about 20 mg, or about 25 mg in the composition.
  • the dapagliflozin citric acid co-crystal is in an effective amount in the pharmaceutical composition.
  • an "effective amount" of an agent, as used herein, is that amount sufficient to effect beneficial or desired results, such as clinical results, and, as such, an "effective amount" depends upon the context in which it is being applied.
  • the pharmaceutically acceptable excipients are selected from one or more of a diluent, a binder, a disintegrant, a lubricant, and mixtures thereof. In some embodiments, the pharmaceutical composition is free of binder.
  • the disclosure of the present inventions provides compositions with increase stability over time, increased stability at various temperatures and/or increased stability at various humidity levels.
  • the present disclosure provides compositions stable for 3 months, 6 months, 9 months, 12 months, 15 months, 18 months or 24 months when stored at 30°C at 65% relative humidity ("RH").
  • RH relative humidity
  • the present disclosure provides compositions stable for 3 months, 6 months, 9 months, 12 months, 15 months, 18 months or 24 months when stored at 40°C at 75% RH.
  • the compositions are stable for three months when stored at 30°C and 65% relative humidity ("RH"). In some embodiments, the compositions stable for three months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for three months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for three months when stored at 40°C and 75% RH and when stored at 40°C and 75% RH.
  • RH relative humidity
  • the compositions are stable for six months when stored at 30°C and 65% relative humidity ("RH"). In some embodiments, the compositions are stable for six months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for six months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for six months when stored at 40°C and 75% RH and when stored at 40°C and 75% RH.
  • RH relative humidity
  • the compositions are stable for six months when stored at 40°C and 75% RH.
  • the compositions are stable for nine months when stored at 30°C and 65% relative humidity ("RH"). In some embodiments, the compositions are stable for nine months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for nine months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for nine months when stored at 40°C and 75% RH and when stored at 40°C and 75% RH.
  • RH relative humidity
  • the compositions are stable for twelve months when stored at 30°C and 65% relative humidity ("RH"). In some embodiments, the compositions are stable for twelve months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for twelve months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for twelve months when stored at 40°C and 75% RH and when stored at 40°C and 75% RH.
  • RH relative humidity
  • the term " stable" refers to a pharmaceutical composition, e.g., dosage form, in which at least 85%, at least 90%, at least 95% or at least 96% of the active agent, e.g., dapagliflozin, remains active at the designated time period compared to the original amount of active agent.
  • the term “stable” refers to a pharmaceutical composition comprising impurities less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, less than 0.3%, or less than 0.2% wt/wt as determined by HPLC at the termination of the designated time period compared to the original amount of active agent as determined by HPLC.
  • the disclosure provides for a pharmaceutical composition having a rapidly dissolving in vitro dissolution profile.
  • dissolution is determined in 1000 mL pH 4.5 acetate buffer using USP apparatus Type-I at 60 RPM, at 37°C ⁇ 0.5°C.
  • the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 10 minutes, not less than 80%, 85%, 90%, or 92% of drug is released.
  • the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 10 minutes, not less than 85% of drug is released.
  • the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 10 minutes, not less than 90% of drug is released. In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 15 minutes, not less than 80%, 85%, 90%, 92% or 94% of drug is released. In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 15 minutes, not less than 85% of drug is released. In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 15 minutes, not less than 92% of drug is released.
  • the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 30 minutes, not less than 90%, 92%, 94%, 96% or 98% of drug is released. In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 30 minutes, not less than 95% of drug is released. In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 30 minutes, not less than 98% of drug is released.
  • the disclosure provides for a rapidly dissolving, stable pharmaceutical composition, e.g., dosage form, comprising:
  • the disclosure provides for a rapidly dissolving, stable pharmaceutical composition, e.g., dosage form, comprising:
  • the disclosure provides for a rapidly dissolving, stable pharmaceutical composition comprising an intragranular part, and an extragranular part, the intragranular part comprising:
  • the intragranular part does not exceed 100%; and the extragranular part comprising:
  • the extragranular part does not exceed 100%; and wherein the composition comprises about 60% to about 95% intragranular part, and about 5% to about 40% extragranular part. In some embodiments, the composition comprises about 75% to about 90% intragranular part, and about 10% to about 25% extragranular part, or about 80% to intragranular part, and about 20% extragranular part.
  • intragranular refers to granules comprising the active agent
  • extragranular refers to granules not comprising the active agent.
  • present disclosure provides a process for making an oral pharmaceutical composition comprising:
  • the present disclosure provides a process for making an oral pharmaceutical composition comprising:
  • the present disclosure provides a process for making an oral pharmaceutical composition comprising:
  • the present disclosure provides a method of treating diabetes by administering an oral pharmaceutical composition as described herein comprising dapagliflozin citric acid co-crystal and one or more pharmaceutically acceptable excipients.
  • the method of treatment further comprises administration of an additional anti-diabetic agent.
  • composition includes solid dosage forms such as powder, pellets, mini-tablets, granules, tablets, capsules, and the like.
  • the composition is in the form of powder, granules, tablets, caplet, gelcap, or capsules.
  • dipagliflozin citric acid co-crystal refers to a stoichiometric multi component system comprising dapagliflozin base and citric acid in a stoichiometric ratio of 1 : 1 and connected by non-covalent interactions.
  • the term "dapagliflozin citric acid co-crystal" is as described in
  • the dapagliflozin citric acid co-crystal is present in the composition in an amount of from about 0.5% to about 25% by weight based on the total weight of the composition.
  • the term "dapagliflozin citric acid co-crystal" includes a composition wherein at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least 98% or at least 99% of the dapagliflozin citric acid in the composition is in crystalline form.
  • anti-diabetic agents includes, but is not limited to metformin, pioglitazone, rosiglitazone, sitagliptin, linagliptin, saxagliptin, alogliptin, pramlintide, repaglinide, nateglinide, acarbose, miglitol, glimepiride, glyburide, glipizide, and voglibose.
  • active moiety refers to the dapagliflozin base.
  • 14.7 mg of dapagliflozin citric acid co-crystal corresponds to 10 mg of dapagliflozin base.
  • pharmaceutically acceptable excipients includes diluents, binders, disintegrants, lubricants, glidants, and mixtures thereof.
  • suitable diluents are selected from the group consisting of lactose, e.g., lactose anhydrous and lactose monohydrate; cellulose, e.g.
  • microcrystalline cellulose co-processed microcrystalline cellulose, and powdered cellulose
  • starch e.g., pregelatinized starch, maize starch, rice starch, potato starch, and wheat starch
  • sugar alcohols e.g., mannitol, sorbitol, xylitol, and erythritol
  • inorganic salts e.g., calcium carbonate, calcium phosphate, calcium sulfate, dibasic calcium phosphate, dibasic calcium phosphate anhydrate, dibasic calcium phosphate dihydrate, and tribasic calcium phosphate; and mixtures thereof.
  • the diluents can be present in an amount of from about 20% to about 98% by weight of the composition, preferably from about 30% to about 95% by weight of the composition. In some embodiments, the diluents are about 60% to about 90% by weight of the composition, about 70% to about 90% by weight of the composition, or about 80% to about 90% by weight of the composition.
  • Various binders can be used according to the present disclosure.
  • suitable binders are selected from the group consisting of povidone, copovidone, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, carboxymethyl cellulose sodium, xanthan gum, gum acacia, gum arabic, tragacanth, corn starch, modified corn starch, maize starch, pregelatinized starch, methacrylates, carboxyvinyl polymers, waxes, and mixtures thereof.
  • the binder can be present in an amount of from about 0% to about 30% by weight of the composition, preferably from about 0% to about 20% by weight of the composition.
  • the binders are about 0% to about 10% by weight of the composition, about 0% to about 5% by weight of the composition, or about 0% to about 1% by weight of the composition. In some embodiments, no binder is present in the compositions, i.e., the composition comprises 0% binder.
  • suitable disintegrants are selected from the group consisting of
  • the disintegrant can be present in an amount of from about 0% to about 30% by weight of the composition, preferably from about 0% to about 20% by weight of the composition. In some embodiments, the disintegrants are about 1% to about 10% by weight of the composition, about 1% to about 5% by weight of the composition, or about 5% to about 7% by weight of the composition.
  • suitable lubricants are selected from the group consisting of stearic acid, magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, polyethylene glycol, talc, hydrogenated vegetable oils, fatty acids, waxes, and mixtures thereof.
  • the lubricant can be present in an amount of from about 0.1% to about 10% by weight of the composition, preferably from about 0.1% to about 5% by weight of the composition. In some embodiments, the lubricant is about 0.01% to about 5% by weight of the
  • glidants can be used according to the present disclosure.
  • suitable glidants or anti-sticking agents are selected from the group consisting of talc, silicon dioxide, colloidal silicon dioxide (colloidal anhydrous silica), calcium silicate, magnesium silicate, hydrated silica, and mixtures thereof.
  • the glidant can be present in an amount of from about 0.1% to about 10% by weight of the composition, preferably from about 0.1% to about 5% by weight of the composition.
  • the lubricant is about 0% to about 5% by weight of the composition, about 0.1% to about 5% by weight of the composition, or about 1% to about 2% by weight of the composition.
  • the oral pharmaceutical composition may be prepared by a wet granulation process or by a dry process such as direct compression and dry granulation.
  • the pharmaceutical composition is prepared by a dry process.
  • the composition can have a coating, or optionally can be uncoated.
  • the oral pharmaceutical composition is further film-coated using techniques well known in the art, such as spray coating in a conventional coating pan or dip coating.
  • the film coat comprises film- forming polymers and one or more coating additives.
  • the target weight gain after the coating can vary between 1% and 10% by weight of the uncoated composition, between 1.5% and 6% by weight of the uncoated composition, or between 2% and 4% by weight of the uncoated composition.
  • Suitable film- forming polymers are selected from the group comprising cellulose derivatives, e.g., methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxymethylethyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose, and ethyl cellulose; vinyl polymers, e.g. ,
  • the film-coating provides for immediate release, extended release, sustained release, delayed release, enteric release, or intestinal release of the active agent, e.g., dapagliflozin citric acid co-crystal, to the subject in which the dosage form was administered.
  • the film-coating provides for immediate release of the active agent.
  • delayed release refers to a pharmaceutical preparation, e.g., an orally administered formulation, which passes through the stomach substantially intact and dissolves in the small and/or large intestine (e.g., the colon).
  • delayed release of the active agent results from the use of an enteric coating of an oral medication (e.g., an oral dosage form).
  • an enteric coating of an oral medication e.g., an oral dosage form.
  • extended release results in substantially constant blood levels of a drug over an extended time period that are within therapeutic levels.
  • enteric release refer to pharmaceutical compositions, e.g., oral dosage forms, for oral administration able to provide protection from dissolution in the high acid (low pH) environment of the stomach. Enteric formulations can be obtained by, for example, incorporating into the
  • the pharmaceutical composition a polymer resistant to dissolution in gastric juices.
  • the polymers have an optimum pH for dissolution in the range of approximately 5.0 to 7.0 ("pH sensitive polymers").
  • the film coating comprises one or more of plasticizers, glidants or flow regulators, lubricants, coloring agents, and opacifiers.
  • Suitable plasticizers are selected from the group comprising castor oil, diacetylated monoglycerides, dibutyl sebacate, diethyl phthalate, glycerin, polyethylene glycols, propylene glycols, triacetin, triethyl citrate, and mixtures thereof.
  • An opacifier like titanium dioxide, may also be present in the coating.
  • solvents used for preparing the coating solution are selected from purified water, methyl alcohol, ethyl alcohol, isopropyl alcohol, n-butyl alcohol, acetone, acetonitrile, chloroform, methylene chloride, and mixtures thereof.
  • the oral pharmaceutical composition will be bioequivalent to the marketed formulation of dapagliflozin (as propanediol monohydrate) available under the brand name Farxiga ® (AstraZeneca, United Kingdom).
  • the oral pharmaceutical composition is used for treating diabetes, particularly Type 1 diabetes
  • the pharmaceutical composition may be administered in combination with other anti-diabetic agents.
  • Various regimens are known to those in the art.
  • the oral pharmaceutical composition is administered once daily.
  • the oral pharmaceutical composition is administered twice daily.
  • the oral pharmaceutical composition is administered every other day.
  • the pharmaceutical composition can be divided (e.g., split in half), with one or more of the divided parts taken at the same time or at different times.
  • crospovidone crospovidone, and silicon dioxide were mixed in a blender.
  • step 2 was compressed into tablets.
  • Example 1 The tablets of Example 1 were subjected to an in-vitro dissolution study in 1000 mL of pH 4.5 acetate buffer at 37°C ⁇ 0.5° C for 30 minutes, using USP apparatus Type-I at 60 RPM. The results are given in Table 1 below:
  • crospovidone and silicon dioxide were mixed in a blender.
  • step 2 was compressed into tablets.
  • An Opadry ® dispersion was prepared, and the tablets of step 3 were coated to a weight build-up of 2% to 4% w/w.
  • Tablets prepared according to Example 2 were stored at 30°C and 65% RH and at
  • step 2 Compact the blend of step 1 followed by milling to obtain granules.
  • step 3 Dry and mill the granules obtained in step 3.
  • step 5 Add extragranular microcrystalline cellulose and crospovidone to the granules of step 4, and mixed.

Abstract

The present disclosure relates to oral pharmaceutical compositions comprising dapagliflozin citric acid co-crystal and one or more pharmaceutically acceptable excipients, and processes for their preparation. It further relates to a method of treating diabetes using said pharmaceutical compositions.

Description

PHARMACEUTICAL COMPOSITION OF DAPAGLIFLOZIN CO-CRYSTAL
Field of the Invention
The present disclosure relates to oral pharmaceutical compositions comprising dapagliflozin citric acid co-crystal and one or more pharmaceutically acceptable excipients, and processes for their preparation. The disclosure further relates to methods of treating diabetes using said pharmaceutical compositions.
Background of the Invention
Dapagliflozin is a SGLT2 inhibitor, chemically known as (25,3R,4R,55,6R)-2-[4- chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol. Current commercially available formulations of dapagliflozin contain a propanediol (propylene glycol) monohydrate solvate of dapagliflozin as the active ingredient. The commercially available dapagliflozin is crystalline in nature. In contrast, dapagliflozin base can exist in amorphous form.
U.S. Patent No. 6,515,117 reports the compound dapagliflozin. U.S. Patent No. 7,919,598 reports a (S)-propylene glycol solvate of dapagliflozin and processes of preparation thereof.
U.S. Patent Nos. 7,851 ,502, 8,221 ,786, and 8,361 ,972 reports pharmaceutical compositions comprising dapagliflozin or dapagliflozin propylene glycol hydrate and specific excipients in given amounts. U.S. Patent No. 8,221 ,786 further reports pharmaceutical compositions in the form of a stock granulation comprising dapagliflozin propylene glycol hydrate and excipients.
PCT Publication No. WO 2012/163546 reports pharmaceutical compositions comprising cyclodextrin and dapagliflozin, in some embodiments as an inclusion complex.
PCT Publication No. WO 2015/011113 reports pharmaceutical compositions comprising amorphous solid dispersions of dapagliflozin or adsorbates of dapagliflozin with one or more pharmaceutically acceptable excipients.
PCT Publication No. WO 2015/104658 reports an amorphous form of
dapagliflozin and a solid dispersion comprising the same.
A novel co-crystal of dapagliflozin with citric acid was reported in PCT
Publication no. WO 2015/198227, which is hereby incorporated by reference in its entirety. Such co-crystals were reported to have higher solubility, good storage stability, and better handling and processing ability due to their non-hygroscopic nature when compared to other polymorphic forms. Such co-crystals were reported to be useful in the treatment of patients with diabetes.
Summary of the Invention
The present disclosure relates to oral pharmaceutical compositions comprising dapagliflozin citric acid co-crystal and one or more pharmaceutically acceptable excipients. In some embodiments, the dapagliflozin citric acid co-crystal is present in an amount of from about 0.5% to about 25% in weight of the active moiety, based on the total weight of the composition. In some embodiments, the oral pharmaceutical composition of the present invention is prepared by a wet granulation process or by a dry process, such as direct compression and dry granulation.
Detailed Description of the Invention
The present disclosure provides oral pharmaceutical formulations comprising dapagliflozin citric acid co-crystal, especially a solid oral dosage form, such that the therapeutic benefits of the dapagliflozin may be delivered to a patient in need thereof. In some embodiments, the present invention provides a stable oral pharmaceutical formulation which is easy to manufacture, provides an acceptable dose uniformity, and provides a rapid dissolution profile. In some embodiments, the disclosure provides an oral pharmaceutical composition comprising dapagliflozin citric acid co-crystal and one or more pharmaceutically acceptable excipients.
According to some embodiments, the dapagliflozin citric acid co-crystal is from about 0.5% to about 25%, about 1% to about 20%, about 2% to about 15%, about 3% to about 10%, or about 4% to about 8% by weight of the total weight of the composition. According to some embodiments, the dapagliflozin citric acid co-crystal is from about 0.5% to about 25% by weight of the total weight of the composition. In some
embodiments, the dapagliflozin citric acid co-crystal is from about 4% to about 8% by weight of the total weight of the composition. Unless indicated otherwise, "%" and "percentage" when referring to amounts of active agent or excipients (e.g., diluents, disintegrants, lubricants, glidants, etc.) refers to wt%, e.g., the weight of the active agent or excipient relative to the weight of the total composition. According to some embodiments, the dapagliflozin citric acid co-crystal is present in an amount of from about 1 mg to about 100 mg, about 2 mg to about 75 mg, about 3 mg to about 50 mg, about 4 mg to about 40 mg, about 5 mg to about 25 mg in the
composition, e.g., a single dosage form. In some embodiments, the dapagliflozin citric acid co-crystal is present in an amount of about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 12 mg, about 15 mg, about 20 mg, or about 25 mg in the composition. In some embodiments, the dapagliflozin citric acid co-crystal is in an effective amount in the pharmaceutical composition. The term an "effective amount" of an agent, as used herein, is that amount sufficient to effect beneficial or desired results, such as clinical results, and, as such, an "effective amount" depends upon the context in which it is being applied.
In some embodiments, the pharmaceutically acceptable excipients are selected from one or more of a diluent, a binder, a disintegrant, a lubricant, and mixtures thereof. In some embodiments, the pharmaceutical composition is free of binder.
In some embodiments, the disclosure of the present inventions provides compositions with increase stability over time, increased stability at various temperatures and/or increased stability at various humidity levels. For example, in some embodiments, the present disclosure provides compositions stable for 3 months, 6 months, 9 months, 12 months, 15 months, 18 months or 24 months when stored at 30°C at 65% relative humidity ("RH"). In some embodiments, the present disclosure provides compositions stable for 3 months, 6 months, 9 months, 12 months, 15 months, 18 months or 24 months when stored at 40°C at 75% RH.
In some embodiments, the compositions are stable for three months when stored at 30°C and 65% relative humidity ("RH"). In some embodiments, the compositions stable for three months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for three months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for three months when stored at 40°C and 75% RH and when stored at 40°C and 75% RH.
In some embodiments, the compositions are stable for six months when stored at 30°C and 65% relative humidity ("RH"). In some embodiments, the compositions are stable for six months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for six months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for six months when stored at 40°C and 75% RH and when stored at 40°C and 75% RH.
In some embodiments, the compositions are stable for nine months when stored at 30°C and 65% relative humidity ("RH"). In some embodiments, the compositions are stable for nine months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for nine months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for nine months when stored at 40°C and 75% RH and when stored at 40°C and 75% RH.
In some embodiments, the compositions are stable for twelve months when stored at 30°C and 65% relative humidity ("RH"). In some embodiments, the compositions are stable for twelve months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for twelve months when stored at 40°C and 75% RH. In some embodiments, the compositions are stable for twelve months when stored at 40°C and 75% RH and when stored at 40°C and 75% RH.
In some embodiments, the term " stable " refers to a pharmaceutical composition, e.g., dosage form, in which at least 85%, at least 90%, at least 95% or at least 96% of the active agent, e.g., dapagliflozin, remains active at the designated time period compared to the original amount of active agent. In some embodiments, the term "stable" refers to a pharmaceutical composition comprising impurities less than 0.8%, less than 0.7%, less than 0.6%, less than 0.5%, less than 0.4%, less than 0.3%, or less than 0.2% wt/wt as determined by HPLC at the termination of the designated time period compared to the original amount of active agent as determined by HPLC.
In some embodiments, the disclosure provides for a pharmaceutical composition having a rapidly dissolving in vitro dissolution profile. In some embodiments as described herein, dissolution is determined in 1000 mL pH 4.5 acetate buffer using USP apparatus Type-I at 60 RPM, at 37°C ±0.5°C. In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 10 minutes, not less than 80%, 85%, 90%, or 92% of drug is released. In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 10 minutes, not less than 85% of drug is released. In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 10 minutes, not less than 90% of drug is released. In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 15 minutes, not less than 80%, 85%, 90%, 92% or 94% of drug is released. In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 15 minutes, not less than 85% of drug is released. In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 15 minutes, not less than 92% of drug is released.
In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 30 minutes, not less than 90%, 92%, 94%, 96% or 98% of drug is released. In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 30 minutes, not less than 95% of drug is released. In some embodiments, the composition exhibits a rapidly dissolving in vitro dissolution profile, such that after 30 minutes, not less than 98% of drug is released.
In some embodiments, the disclosure provides for a rapidly dissolving, stable pharmaceutical composition, e.g., dosage form, comprising:
(i) from about 1% to about 25% dapagliflozin citric acid co-crystal;
(ii) from about 40% to about 90% diluent;
(iii) from about 2% to about 20% disintegrant;
(iv) from about 0.5% to about 5% glidant; and
(v) about 0.1% to about 3% lubricant,
wherein the total composition does not exceed 100%.
In some embodiments, the disclosure provides for a rapidly dissolving, stable pharmaceutical composition, e.g., dosage form, comprising:
(i) from about 1% to about 25% dapagliflozin citric acid co-crystal;
(ii) from about 40% to about 90% microcrystalline cellulose, lactose, or
combinations thereof;
(iii) from about 2% to about 20% crospovidone;
(iv) from about 0.5% to about 5% silicon dioxide; and
(v) about 0.1% to about 3% magnesium stearate, sodium stearyl fumarate, or combinations thereof,
wherein the total composition does not exceed 100%. In some embodiments, the disclosure provides for a rapidly dissolving, stable pharmaceutical composition comprising an intragranular part, and an extragranular part, the intragranular part comprising:
(i) from about 1% to about 25% dapagliflozin citric acid co-crystal;
(ϋ) from about 40% to about 90% diluent;
(iii) from about 2% to about 20% disintegrant;
(iv) from about 0.5% to about 5% glidant; and
(v) from about 0.1% to about 3% lubricant,
wherein the intragranular part does not exceed 100%; and the extragranular part comprising:
(i) from about 60% to about 95% diluent;
(ii) from about 5% to about 30% disintegrant;
(iii) from about 1% to about 10% glidant; and
(iv) from about 0.1% to about 3% lubricant,
wherein the extragranular part does not exceed 100%; and wherein the composition comprises about 60% to about 95% intragranular part, and about 5% to about 40% extragranular part. In some embodiments, the composition comprises about 75% to about 90% intragranular part, and about 10% to about 25% extragranular part, or about 80% to intragranular part, and about 20% extragranular part. The term "intragranular" refers to granules comprising the active agent, and the term "extragranular" refers to granules not comprising the active agent.
In some embodiments, present disclosure provides a process for making an oral pharmaceutical composition comprising:
(a) mixing dapagliflozin citric acid co-crystal with one or more pharmaceutically acceptable excipients to form a blend; and
(b) directly compressing the blend of (a) into a solid dosage form.
In some embodiments, the present disclosure provides a process for making an oral pharmaceutical composition comprising:
(a) mixing dapagliflozin citric acid co-crystal with one or more pharmaceutically acceptable excipients to form a blend;
(b) compacting the blend of (a) into a slug or a compact; (c) milling the slug or compact of (b) into granules;
(d) optionally mixing the granules of (c) with further pharmaceutically acceptable excipients to form a final blend; and
(e) optionally compressing the final blend of (d) into a solid dosage form.
In some embodiments, the present disclosure provides a process for making an oral pharmaceutical composition comprising:
(a) mixing dapagliflozin citric acid co-crystal with one or more pharmaceutically acceptable excipients to form a blend;
(b) granulating the blend of (a) with a granulating liquid to obtain granules;
(c) drying the granules of (b) to obtain dried granules;
(d) optionally milling the dried granules of (c);
(e) adding at least one lubricant to the granules of (c) or the milled material of (d), and optionally mixing with further pharmaceutically acceptable excipients to form a final blend; and
(f) optionally compressing the final blend of (d) into a solid dosage form.
In some embodiments, the present disclosure provides a method of treating diabetes by administering an oral pharmaceutical composition as described herein comprising dapagliflozin citric acid co-crystal and one or more pharmaceutically acceptable excipients.
According to one embodiment, the method of treatment further comprises administration of an additional anti-diabetic agent.
The term "pharmaceutical composition," as used herein, includes solid dosage forms such as powder, pellets, mini-tablets, granules, tablets, capsules, and the like. In some embodiments, the composition is in the form of powder, granules, tablets, caplet, gelcap, or capsules.
The term "dapagliflozin citric acid co-crystal," as used herein, refers to a stoichiometric multi component system comprising dapagliflozin base and citric acid in a stoichiometric ratio of 1 : 1 and connected by non-covalent interactions. In some embodiments, the term "dapagliflozin citric acid co-crystal" is as described in
WO 2015/198227, incorporated herein in its entirely. In some embodiments, the dapagliflozin citric acid co-crystal is present in the composition in an amount of from about 0.5% to about 25% by weight based on the total weight of the composition. One of skill in the art will appreciate that not 100% of the dapagliflozin citric acid necessarily will be in crystalline form. Thus, as used herein, in some embodiments the term "dapagliflozin citric acid co-crystal" includes a composition wherein at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least 98% or at least 99% of the dapagliflozin citric acid in the composition is in crystalline form.
The term "anti-diabetic agents," as used herein, includes, but is not limited to metformin, pioglitazone, rosiglitazone, sitagliptin, linagliptin, saxagliptin, alogliptin, pramlintide, repaglinide, nateglinide, acarbose, miglitol, glimepiride, glyburide, glipizide, and voglibose.
The term "about," as used herein, refers to any value which lies within the range defined by a variation of up to ±10% of the value.
The term "active moiety," as used herein, refers to the dapagliflozin base. For example, 14.7 mg of dapagliflozin citric acid co-crystal corresponds to 10 mg of dapagliflozin base.
The term "pharmaceutically acceptable excipients," as used herein, includes diluents, binders, disintegrants, lubricants, glidants, and mixtures thereof.
Various diluents can be used. In some embodiments, suitable diluents are selected from the group consisting of lactose, e.g., lactose anhydrous and lactose monohydrate; cellulose, e.g. , microcrystalline cellulose, co-processed microcrystalline cellulose, and powdered cellulose; starch, e.g., pregelatinized starch, maize starch, rice starch, potato starch, and wheat starch; sugar alcohols, e.g., mannitol, sorbitol, xylitol, and erythritol; inorganic salts, e.g., calcium carbonate, calcium phosphate, calcium sulfate, dibasic calcium phosphate, dibasic calcium phosphate anhydrate, dibasic calcium phosphate dihydrate, and tribasic calcium phosphate; and mixtures thereof. The diluents can be present in an amount of from about 20% to about 98% by weight of the composition, preferably from about 30% to about 95% by weight of the composition. In some embodiments, the diluents are about 60% to about 90% by weight of the composition, about 70% to about 90% by weight of the composition, or about 80% to about 90% by weight of the composition. Various binders can be used according to the present disclosure. In some embodiments, suitable binders are selected from the group consisting of povidone, copovidone, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, methyl cellulose, ethyl cellulose, carboxymethyl cellulose sodium, xanthan gum, gum acacia, gum arabic, tragacanth, corn starch, modified corn starch, maize starch, pregelatinized starch, methacrylates, carboxyvinyl polymers, waxes, and mixtures thereof. The binder can be present in an amount of from about 0% to about 30% by weight of the composition, preferably from about 0% to about 20% by weight of the composition. In some embodiments, the binders are about 0% to about 10% by weight of the composition, about 0% to about 5% by weight of the composition, or about 0% to about 1% by weight of the composition. In some embodiments, no binder is present in the compositions, i.e., the composition comprises 0% binder.
Various disintegrants can be used according to the present disclosure. In some embodiments, suitable disintegrants are selected from the group consisting of
croscarmellose sodium, hydroxypropyl cellulose, crospovidone, low substituted hydroxypropyl cellulose, microcrystalline cellulose, carboxymethyl cellulose sodium, carboxymethyl cellulose calcium, starch, corn starch, pregelatinized starch, modified starch, sodium starch glycolate, carboxymethyl starch, poly aery lates, and mixtures thereof. The disintegrant can be present in an amount of from about 0% to about 30% by weight of the composition, preferably from about 0% to about 20% by weight of the composition. In some embodiments, the disintegrants are about 1% to about 10% by weight of the composition, about 1% to about 5% by weight of the composition, or about 5% to about 7% by weight of the composition.
Various lubricants can be used according to the present disclosure. In some embodiments, suitable lubricants are selected from the group consisting of stearic acid, magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, polyethylene glycol, talc, hydrogenated vegetable oils, fatty acids, waxes, and mixtures thereof. The lubricant can be present in an amount of from about 0.1% to about 10% by weight of the composition, preferably from about 0.1% to about 5% by weight of the composition. In some embodiments, the lubricant is about 0.01% to about 5% by weight of the
composition, about 0.1 % to about 2% by weight of the composition, or about 1 % to about 2% by weight of the composition. Various glidants can be used according to the present disclosure. In some embodiments, suitable glidants or anti-sticking agents are selected from the group consisting of talc, silicon dioxide, colloidal silicon dioxide (colloidal anhydrous silica), calcium silicate, magnesium silicate, hydrated silica, and mixtures thereof. The glidant can be present in an amount of from about 0.1% to about 10% by weight of the composition, preferably from about 0.1% to about 5% by weight of the composition. In some embodiments, the lubricant is about 0% to about 5% by weight of the composition, about 0.1% to about 5% by weight of the composition, or about 1% to about 2% by weight of the composition.
The oral pharmaceutical composition may be prepared by a wet granulation process or by a dry process such as direct compression and dry granulation. Preferably, the pharmaceutical composition is prepared by a dry process. The composition can have a coating, or optionally can be uncoated. In some embodiments, the oral pharmaceutical composition is further film-coated using techniques well known in the art, such as spray coating in a conventional coating pan or dip coating. The film coat comprises film- forming polymers and one or more coating additives. The target weight gain after the coating can vary between 1% and 10% by weight of the uncoated composition, between 1.5% and 6% by weight of the uncoated composition, or between 2% and 4% by weight of the uncoated composition.
Suitable film- forming polymers are selected from the group comprising cellulose derivatives, e.g., methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxymethylethyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose, and ethyl cellulose; vinyl polymers, e.g. ,
polyvinylpyrrolidones; acrylic polymers; and mixtures thereof. Alternatively, commercially available coating compositions comprising film- forming polymers marketed under various trade names, e.g., Opadry®, may be used for coating.
In some embodiments, the film-coating provides for immediate release, extended release, sustained release, delayed release, enteric release, or intestinal release of the active agent, e.g., dapagliflozin citric acid co-crystal, to the subject in which the dosage form was administered. In some embodiments, the film-coating provides for immediate release of the active agent. As used herein, the term "delayed release" refers to a pharmaceutical preparation, e.g., an orally administered formulation, which passes through the stomach substantially intact and dissolves in the small and/or large intestine (e.g., the colon). In some embodiments, delayed release of the active agent (e.g., dapagliflozin citric acid co-crystal as described herein) results from the use of an enteric coating of an oral medication (e.g., an oral dosage form). The terms "extended release" or "sustained release"
interchangeably refer to a drug formulation that provides for gradual release of a drug over an extended period of time, e.g., 6-12 hours or more, compared to an immediate release formulation of the same drug. In some embodiments, although not necessarily, extended release results in substantially constant blood levels of a drug over an extended time period that are within therapeutic levels. As used herein, the terms "enteric release" refer to pharmaceutical compositions, e.g., oral dosage forms, for oral administration able to provide protection from dissolution in the high acid (low pH) environment of the stomach. Enteric formulations can be obtained by, for example, incorporating into the
pharmaceutical composition a polymer resistant to dissolution in gastric juices. In some embodiments, the polymers have an optimum pH for dissolution in the range of approximately 5.0 to 7.0 ("pH sensitive polymers").
The film coating", "film" or "coating additives comprise one or more of plasticizers, glidants or flow regulators, lubricants, coloring agents, and opacifiers.
Suitable plasticizers are selected from the group comprising castor oil, diacetylated monoglycerides, dibutyl sebacate, diethyl phthalate, glycerin, polyethylene glycols, propylene glycols, triacetin, triethyl citrate, and mixtures thereof. An opacifier, like titanium dioxide, may also be present in the coating.
Examples of solvents used for preparing the coating solution are selected from purified water, methyl alcohol, ethyl alcohol, isopropyl alcohol, n-butyl alcohol, acetone, acetonitrile, chloroform, methylene chloride, and mixtures thereof.
The oral pharmaceutical composition will be bioequivalent to the marketed formulation of dapagliflozin (as propanediol monohydrate) available under the brand name Farxiga® (AstraZeneca, United Kingdom).
The oral pharmaceutical composition is used for treating diabetes, particularly Type
II diabetes. The pharmaceutical composition may be administered in combination with other anti-diabetic agents. Various regimens are known to those in the art. In some embodiments, the oral pharmaceutical composition is administered once daily. In some embodiments, the oral pharmaceutical composition is administered twice daily. In some embodiments, the oral pharmaceutical composition is administered every other day. One of skill in the art can also appreciate that in some embodiments, the pharmaceutical composition can be divided (e.g., split in half), with one or more of the divided parts taken at the same time or at different times.
The present invention is illustrated below by reference to the following examples. However, one skilled in the art will appreciate that the specific methods and results discussed are merely illustrative of the invention, and not to be construed as limiting the invention, as many variations thereof are possible without departing from the spirit and scope of the invention.
EXAMPLES
Example 1:
Figure imgf000013_0001
Procedure:
1. Dapagliflozin citric acid co-crystal, microcrystalline cellulose, lactose,
crospovidone, and silicon dioxide were mixed in a blender.
2. Magnesium stearate was added to the above blend in the blender and mixed.
3. The blend of step 2 was compressed into tablets.
4. An Opadry® dispersion was prepared, and the tablets of step 3 were coated to a weight build-up of 2% to 4% w/w. Dissolution Study
The tablets of Example 1 were subjected to an in-vitro dissolution study in 1000 mL of pH 4.5 acetate buffer at 37°C ±0.5° C for 30 minutes, using USP apparatus Type-I at 60 RPM. The results are given in Table 1 below:
Table 1. Dissolution profile of tablets of Example 1
Figure imgf000014_0001
Example 2:
Figure imgf000014_0002
Procedure:
1. Dapagliflozin citric acid co-crystal, microcrystalline cellulose, lactose,
crospovidone and silicon dioxide were mixed in a blender.
2. Magnesium stearate was added to the above blend in the blender and mixed.
3. The blend of step 2 was compressed into tablets.
4. An Opadry® dispersion was prepared, and the tablets of step 3 were coated to a weight build-up of 2% to 4% w/w.
Stability Data:
Tablets prepared according to Example 2 were stored at 30°C and 65% RH and at
40°C and 75% RH for six months, and were then tested by HPLC to determine the amount of total impurities. The stability data is given in Table 2. Table 2. Stability data of the tablets of Example 2.
Figure imgf000015_0001
Examples 3-4:
Figure imgf000015_0002
Procedure:
Blend Dapagliflozin citric acid co-crystal, microcrystalline cellulose, lactose, povidone, crospovidone, and silicon dioxide in a blender.
Add Magnesium stearate or sodium stearyl fumarate to the above blend in the blender and mixed.
Compress the blend of step 2 into tablets.
Prepare Opadry® dispersion and coat the tablets of step 3 to a weight build-up of 2% to 4% w/w.
Example 5:
Figure imgf000016_0001
Procedure:
1. Blend Dapagliflozin citric acid co-crystal, microcrystalline cellulose, lactose anhydrous, crospovidone, and silicon dioxide in a blender.
2. Compact the blend of step 1 followed by milling to obtain granules.
3. Blend the extra granular excipients with the granules obtained in step 2.
4. Compress the blend of step 3 into tablets.
5. Prepare Opadry® dispersion, and coat the tablets of step 4 with the Opadry® dispersion to a weight build-up of 2% to 4% w/w.
Examples 6-8:
Figure imgf000017_0001
Procedure:
1. Blend lactose anhydrous/monohydrate, microcrystalline cellulose, and
dapagliflozin citric acid co-crystal in a blender.
2. Dissolve Hydroxypropyl cellulose or hydroxypropylmethyl cellulose or povidone in a solvent mixture or purified water to obtain a binder solution.
3. Granulate the material of step 1 with the binder solution of step 2.
4. Dry and mill the granules obtained in step 3.
5. Add extragranular microcrystalline cellulose and crospovidone to the granules of step 4, and mixed.
6. Add colloidal anhydrous silica and magnesium stearate to the material of step 5, and mixed.
7. Compress the blend of step 6 into tablets.
8. Prepare Opadry® dispersion and coat the tablets of step 7 with the Opadry® dispersion to a weight build-up of 2% to 4% w/w.

Claims

We Claim:
1. An oral pharmaceutical composition comprising dapagliflozin citric acid co-crystal and one or more pharmaceutically acceptable excipients, wherein the dapagliflozin citric acid co-crystal is from about 0.5% to about 25% by weight of the total weight of the composition.
2. The oral pharmaceutical composition according to claim 1 , wherein the dapagliflozin citric acid co-crystal in the pharmaceutical composition is from about 1 mg to about 100 mg.
3. The oral pharmaceutical composition according to any one of claims 1 to 2, wherein the pharmaceutically acceptable excipients are selected from one or more of diluents, binders, disintegrants, lubricants, and mixtures thereof.
4. The oral pharmaceutical composition according to any one of claims 1 to 3, wherein the composition is free of binder.
5. The oral pharmaceutical composition according to any one of claims 1 to 4, wherein the composition is in the form of powder, pellets, mini-tablets, granules, tablets, or capsules.
6. The oral pharmaceutical composition according to any one of claims 1 to 5, wherein the composition further comprises a film-coating.
7. The oral pharmaceutical composition according to any one of claims 1 to 6, wherein the composition is stable for six months when stored at 30°C and 65% RH or 40°C and 75% RH.
8. The oral pharmaceutical composition according to any one of claims 1 to 7, wherein the composition exhibits a rapidly dissolving in-vitro release profile.
9. The oral pharmaceutical composition according to claim 8, wherein the composition releases not less than 85% of the drug in 15 minutes, when tested in 1000 mL pH 4.5 acetate buffer using USP apparatus Type-I at 60 RPM, at 37°C ±0.5°C.
10. The oral pharmaceutical composition according to any one of claims 1 to 9, wherein the composition is bioequivalent to the marketed Farxiga® tablet.
11. The oral pharmaceutical composition according to any one of claims 1 to 10, wherein the composition is prepared by a wet granulation process.
12. The oral pharmaceutical composition according to any one of claims 1 to 10, wherein the composition is prepared by a dry process selected from direct compression and dry granulation.
13. A process of preparing an oral pharmaceutical composition comprising dapagliflozin citric acid co-crystal and one or more pharmaceutically acceptable excipients, wherein the process comprises:
(a) mixing dapagliflozin citric acid co-crystal with one or more pharmaceutically acceptable excipients to form a blend; and
(b) directly compressing the blend of (a) into a solid dosage form.
14. A process of preparing an oral pharmaceutical composition comprising dapagliflozin citric acid co-crystal and one or more pharmaceutically acceptable excipients, wherein the process comprises:
(a) mixing dapagliflozin citric acid co-crystal with one or more pharmaceutically acceptable excipients to form a blend;
(b) granulating the blend of (a) with a granulating liquid to obtain granules; (c) drying the granules of (b) to obtain dried granules;
(d) adding at least one lubricant to the dried granules of step (c) to form a final blend.
15. The process of claim 14, further comprising milling the dried granules of (c).
16. The process of any one of claims 14 or 15, comprising further mixing additional pharmaceutical excipients with the lubricant of (d) to form the final blend.
17. The process of any one of claims 14 to 16, further comprising compressing the final blend of (d) into a solid dosage form.
18. A method of the treatment of type 2 diabetes mellitus, said method comprising
administering an oral pharmaceutical composition according to any one of claims 1 to 17 to a subject in need thereof.
19. The method according to claim 18, wherein method of treatment further comprises administration of an additional anti-diabetic agent.
20. The method according to claim 19, wherein the additional anti-diabetic agent is selected from the group consisting of metformin, pioglitazone, rosiglitazone, sitagliptin, linagliptin, saxagliptin, alogliptin, pramlintide, repaglinide, nateglinide, acarbose, miglitol, glimepiride, glyburide, glipizide, and voglibose.
PCT/IB2017/053155 2016-05-30 2017-05-30 Pharmaceutical composition of dapagliflozin co-crystal WO2017208136A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020237012428A KR20230056789A (en) 2016-05-30 2017-05-30 Pharmaceutical composition of dapagliflozin co-crystal
KR1020187036843A KR20190015329A (en) 2016-05-30 2017-05-30 A pharmaceutical composition of a dapagliflozin co-crystal

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201611018449 2016-05-30
IN201611018449 2016-05-30

Publications (1)

Publication Number Publication Date
WO2017208136A1 true WO2017208136A1 (en) 2017-12-07

Family

ID=60478087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/053155 WO2017208136A1 (en) 2016-05-30 2017-05-30 Pharmaceutical composition of dapagliflozin co-crystal

Country Status (2)

Country Link
KR (2) KR20230056789A (en)
WO (1) WO2017208136A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111494328A (en) * 2020-04-07 2020-08-07 乐普制药科技有限公司 Osmotic pump tablet containing acarbose and dapagliflozin and preparation method thereof
CN112206216A (en) * 2020-10-15 2021-01-12 江西华士药业有限公司 Preparation method of sustained-release potent dapagliflozin
WO2021176096A1 (en) * 2020-03-05 2021-09-10 Krka, D.D., Novo Mesto Pharmaceutical composition comprising sglt2 inhibitor
CN113943282A (en) * 2020-07-15 2022-01-18 中国医学科学院药物研究所 Pioglitazone hydrochloride and aminosalicylic acid eutectic crystal, preparation method, composition and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120041069A1 (en) * 2008-10-17 2012-02-16 Nectid Inc. Sglt2 inhibitor dosage forms
US20140249098A1 (en) * 2011-06-03 2014-09-04 Ratiopharm Gmbh Pharmaceutical Composition Comprising Dapagliflozin and Cyclodextrin
US20140343010A1 (en) * 2013-04-29 2014-11-20 Mapi Pharma Ltd. Co-crystals of dapagliflozin
WO2015198227A1 (en) * 2014-06-23 2015-12-30 Sun Pharmaceutical Industries Limited Co-crystal of dapagliflozin with citric acid

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120041069A1 (en) * 2008-10-17 2012-02-16 Nectid Inc. Sglt2 inhibitor dosage forms
US20140249098A1 (en) * 2011-06-03 2014-09-04 Ratiopharm Gmbh Pharmaceutical Composition Comprising Dapagliflozin and Cyclodextrin
US20140343010A1 (en) * 2013-04-29 2014-11-20 Mapi Pharma Ltd. Co-crystals of dapagliflozin
WO2015198227A1 (en) * 2014-06-23 2015-12-30 Sun Pharmaceutical Industries Limited Co-crystal of dapagliflozin with citric acid

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021176096A1 (en) * 2020-03-05 2021-09-10 Krka, D.D., Novo Mesto Pharmaceutical composition comprising sglt2 inhibitor
CN111494328A (en) * 2020-04-07 2020-08-07 乐普制药科技有限公司 Osmotic pump tablet containing acarbose and dapagliflozin and preparation method thereof
CN113943282A (en) * 2020-07-15 2022-01-18 中国医学科学院药物研究所 Pioglitazone hydrochloride and aminosalicylic acid eutectic crystal, preparation method, composition and application thereof
CN113943282B (en) * 2020-07-15 2023-12-19 中国医学科学院药物研究所 Pioglitazone hydrochloride para-aminosalicylic acid eutectic crystal, preparation method, composition and application thereof
CN112206216A (en) * 2020-10-15 2021-01-12 江西华士药业有限公司 Preparation method of sustained-release potent dapagliflozin

Also Published As

Publication number Publication date
KR20230056789A (en) 2023-04-27
KR20190015329A (en) 2019-02-13

Similar Documents

Publication Publication Date Title
JP5788331B2 (en) Pharmaceutical formulations comprising one or more fumarate esters in an erosion matrix
JP6976946B2 (en) A pharmaceutical composition containing an inhibitor of URAT1 having strong bioactivity.
BR112020024203A2 (en) pharmaceutical combination, composition and formulation containing glucokinase activator and a-glucosidase inhibitor, methods of preparation and use thereof
WO2015128853A1 (en) Dapagliflozin compositions
HU231114B1 (en) Pharmaceutical preparations containing mycophenolic acid or mycophenolate
WO2017208136A1 (en) Pharmaceutical composition of dapagliflozin co-crystal
WO2014080384A1 (en) Pharmaceutical composition of linagliptin
US20070104789A1 (en) Gastro-resistant and ethanol-resistant controlled-release formulations comprising hydromorphone
JP2015522653A (en) Pharmaceutical composition of proton pump inhibitor
US11576917B2 (en) Pharmaceutical compositions comprising Ibrutinib
JP2019512537A (en) Pharmaceutical composition of dapagliflozin
US9132092B1 (en) Pharmaceutical composition of doxycycline
WO2015028875A2 (en) Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
WO2011051967A2 (en) Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof
US11331273B2 (en) Film-coated tablet having high chemical stability of active ingredient
US9561242B2 (en) Doxycycline composition
US20080081069A1 (en) Novel controlled release formulations of divalproex sodium
US20110159092A1 (en) Extended release pharmaceutical composition comprising linezolid and process for preparing the same
US20150250734A1 (en) Stable pharmaceutical compositions of saxagliptin or salts thereof
US20100310652A1 (en) Coated extended release pharmaceutical compositions of levetiracetam
WO2017037645A1 (en) Stable pharmaceutical formulations of teriflunomide
US20160143923A1 (en) Low dose pharmaceutical composition of doxycycline
US9566287B2 (en) Pharmaceutical composition of doxycycline with reduced food effect
US20120121722A1 (en) Atazanavir formulations
WO2014096983A1 (en) Stable pharmaceutical compositions of saxagliptin or salts thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17805972

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20187036843

Country of ref document: KR

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 17805972

Country of ref document: EP

Kind code of ref document: A1